nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

16.07.2021 | Nutrition and Obesity (O Pickett-Blakely, Section Editor)

Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery

verfasst von: Chika Vera Anekwe, MD, MPH, Michael G. Knight, MD, MSHP, Sujatha Seetharaman, MD, MPH, Wesley P. Dutton, MD, Shradha M. Chhabria, Fatima Cody Stanford, MD, MPH, MPA, MBA

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

We sought to critically evaluate the recent literature published over the past 3 years on the topic of weight regain after bariatric surgery in children, adolescents, and adults, with an emphasis on clinically relevant information for pharmacologic treatment of weight regain after metabolic and bariatric surgery.

Recent findings

There are multiple pharmacotherapeutic agents available to treat obesity in children, adolescents, and adults; these agents have varying efficacy and indications for use and have been studied in a variety of clinical and research scenarios. We present an overview of these findings.

Summary

This review represents a comprehensive compilation of the recently published data on efficacy of anti-obesity pharmacotherapy in the treatment of weight regain after bariatric surgery for children, adolescents, and adults.

Hales CM, Carrol MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS data brief. 2020;(360).

Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723–5.PubMedPubMedCentralCrossRef

Pedroso FE, Angriman F, Endo A, Dasenbrock H, Storino A, Castillo R, et al. Weight loss after bariatric surgery in obese adolescents: a systematic review and meta-analysis. Surg Obes Relat Dis. 14. United States: © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc; 2018. p. 413-22

Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRefPubMed

Estimate of Bariatric Surgery Numbers, 2011-2018: American Society for Metabolic and Bariatric Surgery; 2018 [updated 2018-06-26. Available from: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers.

Kyler KE, Bettenhausen JL, Hall M, Fraser JD, Sweeney B. Trends in volume and utilization outcomes in adolescent metabolic and bariatric surgery at children’s hospitals. J Adolesc Health. 65. United States: © 2019 Society for Adolescent Health and Medicine. Published by Elsevier Inc; 2019. p. 331-6.

Kizy S, Jahansouz C, Downey MC, Hevelone N, Ikramuddin S, Leslie D. National Trends in bariatric surgery 2012-2015: demographics, procedure selection, readmissions, and cost. Obes Surg. 27. United States 2017. p. 2933-9.

Pratt JSA, Browne A, Browne NT, Bruzoni M, Cohen M, Desai A, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis. 2018;14(7):882–901.PubMedPubMedCentralCrossRef

10.

Who is a Candidate for Bariatric Surgery? : American Society for Metabolic and Bariatric Surgery; 2021 [Available from: https://asmbs.org/patients/who-is-a-candidate-for-bariatric-surgery.

11.

Griggs CL, Perez NP, Goldstone RN, Kelleher CM, Chang DC, Stanford FC, et al. National trends in the use of metabolic and bariatric surgery among pediatric patients with severe obesity. JAMA Pediatr. 2018;172(12):1191–2.PubMedPubMedCentralCrossRef

12.

Bariatric Surgery Procedures: A; 2021 [Available from: https://asmbs.org/patients/bariatric-surgery-procedures.

13.

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87.PubMedPubMedCentralCrossRef

14.

Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 24. United States 2008. p. 832-42.

15•.

. Bastos EC, Barbosa EM, Soriano GM, dos Santos EA, Vasconcelos SM. Determinants of weight regain after bariatric surgery. Arq Bras Cir Dig. 2013:26–32 This study showed that while bariatric surgery promotes adequate reduction of excess body weight, significant weight regain may occur after 5 years, most often correlated with post-operative time and work activity related to eating out.

16.

•• Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500 This study showed weight loss pharmacotherapy is a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain; of the 15 medications evaluated, topiramate was the only medication that demonstrated a statistically significant response for weight loss.PubMedCrossRef

17.

• Cadena-Obando D, Ramírez-Rentería C, Ferreira-Hermosillo A, Albarrán-Sanchez A, Sosa-Eroza E, Molina-Ayala M, et al. Are there really any predictive factors for a successful weight loss after bariatric surgery? BMC Endocr Disord. 2020;20(1):20 This study found that nearly 20% of patients who undergo bariatric surgery will not lose more than 50% excess body weight, and the factors influencing post-operative weight nadir are still controversial but may be population-specific.PubMedPubMedCentralCrossRef

18.

•• Velapati SR, Shah M, Kuchkuntla AR, Abu-Dayyeh B, Grothe K, Hurt RT, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7:329–34 This article reviews the prevalence, etiology and treatment of post-bariatric surgery weight regain and calls for clinicians to counsel patients seeking bariatric surgery on the likelihood of weight regain as well as inform them of treatment options if weight regain occurs.PubMedCrossRef

19.

Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics. 2018;141(3).

20.

Di Cesare M, Sorić M, Bovet P, Miranda JJ, Bhutta Z, Stevens GA, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med. 2019;17(1):212.PubMedPubMedCentralCrossRef

21.

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017(288):1–8.

22.

Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17(2):95–107.PubMedCrossRef

23.

• Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709–57 This concensus statement reviews clinical practice guidelines for the assessment, treatment and prevention of pediatric obesity.PubMedPubMedCentralCrossRef

24.

Novo Nordisk. FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17. Novonordisk-us.com. Published December 4, 2020. Accessed January 7, 2021. https://www.novonordisk-us.com/media/news-releases.html?123001.

25.

• Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397–403 Setmelanotide received its first approval in the United States for chronic weight management in patients 6 years and older.PubMedCrossRef

26.

Armstrong SC, Bolling CF, Michalsky MP, Reichard KW. Section On Obesity SOS. Pediatric metabolic and bariatric surgery: evidence, barriers, and best practices. Pediatrics. 2019;144(6).

27.

Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity (Silver Spring). 2019;27(2):190–204.CrossRef

28.

Inge TH, Jenkins TM, Xanthakos SA, Dixon JB, Daniels SR, Zeller MH, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol. 2017;5(3):165–73.PubMedPubMedCentralCrossRef

29.

Olbers T, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol. 2017;5(3):174–83.PubMedPubMedCentralCrossRef

30.

Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–23.PubMedCrossRef

31.

•• Toth AT, Gomez G, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight Loss Medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Children (Basel). 2018;5(9) This study found that topiramate, phentermine and metformin are promising weight loss medications for young adults aged 21 to 30 years, and those who start medication at the postsurgical nadir as opposed to after weight regain achieved greater weight loss.

32.

Campoverde Reyes KJ, Misra M, Lee H, Stanford FC. Weight loss surgery utilization in patients aged 14-25 with severe obesity among several healthcare institutions in the United States. Front Pediatr. 2018;6:251.PubMedPubMedCentralCrossRef

33.

•• Stanford FC. Controversial issues: a practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss. Surg Obes Relat Dis. 2019;15(1):128–32 This paper provides guidance on how to initiate several anti-obesity medications after weight loss surgery in patients.PubMedCrossRef

34.

•• Nor Hanipah Z, Nasr EC, Bucak E, Schauer PR, Aminian A, Brethauer SA, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8 This study showed that adjuvant weight loss medications halted weight regain in patients who experienced post-bariatric surgical weight regain; the effect was more significant in those who had undergone gastric bypass (compared to gastric sleeve) and those with higher body mass index.PubMedCrossRef

35.

• Sudlow AC, le Roux CW, Pournaras DJ. Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery. Obes Surg. 2019;29(12):4095–104 This review provides an overview of the most recently-developed anti-obesity medications and discusses the opportunities for providing multimodal care using anti-obesity pharmacotherapy in post-bariatric surgical weight regain.CrossRef

36.

Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E. New treatment modalities for obesity. Best Pract Res Clin Endocrinol Metab. 2018;32(4):535–49.PubMedCrossRef

37.

Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61(11):2753–62.PubMedPubMedCentralCrossRef

38.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.PubMedCrossRef

39.

• Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501 This study demonstrated a median weight loss of 6.4% in patients treated with liraglutide, and no significant difference in weight loss between those who had prior bariatric surgery vs those who had not.PubMedCrossRef

40.

•• Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021; This study found that GLP-1 receptor agonist medications were found to be more effective for treating post-bariatric weight regain than non-GLP-1 receptor agonist medications or intensive lifestyle modification, regardless of surgery type.

41.

•• Wharton S, Kuk JL, Luszczynski M, Kamran E, RAG C. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323 This study found that post-bariatric surgery patients can lose a significant amount of weight while taking liraglutide 3.0 mg regardless of the type of surgery they had; like non-surgical populations, post-bariatric surgery patients taking liraglutide 3.0 mg may experience gastrointestinal side effects such as nausea, and can continue to lose weight up to 1 year.PubMedPubMedCentralCrossRef

42.

•• Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8 This study found high-dose liraglutide to be an effective adjunct treatment for weight loss in patients with prior bariatric surgery, showing 16-week median weight loss of 7.1% and 28-week median weight loss of 9.7% body weight.PubMedCrossRef

43.

Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.

44.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989.PubMedCrossRef

45.

Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938–46.PubMedPubMedCentralCrossRef

46.

•• Srivastava G, Buffington C. A specialized medical management program to address post-operative weight regain in bariatric patients. Obes Surg. 2018;28(8):2241–6 This study concluded that a medically supervised weight management program complementary to surgery is beneficial for the treatment of weight regain and is important in assisting the surgical patient in achieving long-term weight loss success.PubMedCrossRef

47.

•• Stanford FC, Toth AT, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8 This study found that weight loss medications are a useful treatment to confer additional weight loss in adults 60 years of age and older after Roux-en-Y gastric bypass and sleeve gastrectomy.PubMedPubMedCentralCrossRef

48.

•• Gutt S, Schraier S, Gonzalez Bagnes MF, Yu M, Gonzalez CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):939–47 This review summarizes the available evidence concerning long-term pharmacotherapy of obesity in patients who have undergone bariatric surgery, finding that initiation of medications at the weight plateau results in higher cumulative total weight loss, and emphasizing the beneficial effects of using pharmacotherapy to prevent and manage post bariatric surgery weight regain.PubMedCrossRef

49.

Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18–28.PubMedCrossRef

50.

Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71.CrossRef

51.

Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef

52.

Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes. 2017;41(1):90–3.CrossRef

53.

Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14(1):12–24.PubMedCrossRef

54.

Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–42.CrossRef

55.

Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013;7:267–78.PubMed

56.

Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A Randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28.PubMedCrossRef

57.

Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM. Mendes de Oliveira E, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321–9.PubMedPubMedCentralCrossRef

58.

Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.PubMedCrossRef

59.

de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.PubMedPubMedCentralCrossRef

60.

Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(9):928–37.PubMedCrossRef

61.

Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.PubMedCrossRef

62.

O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317(23):2427–44.PubMedCrossRef

63.

Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism. 2019;92:170–92.PubMedCrossRef

64.

Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27–31.PubMed

65.

Takeoka M, Riviello JJ, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia. 2002;43(9):1072–5.PubMedCrossRef

66.

Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity (Silver Spring). 2016;24(12):2553–61.CrossRef

67.

Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54(1):19–24.CrossRef

68.

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedCrossRef

69.

Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338–47.PubMedCrossRef

70.

Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs. 2003;16(3):123–30.PubMedCrossRef

71.

Woodard K, Louque L, Hsia DS. Medications for the treatment of obesity in adolescents. Ther Adv Endocrinol Metab. 2020;11:2042018820918789.PubMedPubMedCentralCrossRef

72.

Kweon K, Kim HW. Effectiveness and safety of bupropion in children and adolescents with depressive disorders: a retrospective chart review. Clin Psychopharmacol Neurosci. 2019;17(4):537–41.PubMedPubMedCentralCrossRef

73.

Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633–41.PubMedCrossRef

74.

Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.CrossRef

75.

Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder. Neuropsychopharmacol Rep. 2020;40(1):52–62.PubMedCrossRef

76.

Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, et al. Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2018;32(5):455–67.PubMedPubMedCentralCrossRef

77.

McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–46.PubMedCrossRef

78.

•• Redmond I, Shukla A, Aronne L. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021; This study asserts that adjuvant pharmacotherapy can help treat weight regain after bariatric surgery however future studies are needed to elucidate the optimal timing for starting such medications as well as the best medications or combinations of medications for managing postoperative weight regain.

Titel: Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery
verfasst von: Chika Vera Anekwe, MD, MPH
Michael G. Knight, MD, MSHP
Sujatha Seetharaman, MD, MPH
Wesley P. Dutton, MD
Shradha M. Chhabria
Fatima Cody Stanford, MD, MPH, MPA, MBA
Publikationsdatum: 16.07.2021
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 3/2021
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-021-00358-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Management of Chronic Refractory Oesophageal Strictures

ACLF and Liver Transplantation

Recent Advances in the Artificial Intelligence–Assisted Detection of Esophageal Neoplasia

Endoscopic Anti-Reflux Procedures: Ready for Clinical Use?

Dyspepsia: Treatment Options Directed to Specific Targets